NEWS SEARCH ANALYSIS INSIGHT

360° SearchNetwork Hot Spots Trends

Advanced Search Options >>

Sunday, March 21, 2010 1:05 PM

Biocompatibles International plc

Type: Company

Name: Biocompatibles International plc

Fact Sheet: Fact Sheet for Biocompatibles International plc

First Reported 15 hours ago - Updated 15 hours ago - 1 Documents

NCC AB

Small cap news wrap: ReNeuron Group, Biocompatibles, Medicsight, Blacks Leisure, Fusion IP

Small cap companies performed well thsi week as while the FTSE 100 added less than 1%, the FTSE AIM All-Share Index climbed 1.4% during the week, while the FTSE AIM 100 advanced 1.8%ReNeuron Group (AIM: RENE) has signed two further clinical grade stem ... [Published 15 hours ago by Proactive Investors.co.uk]

Entities: Biocompatibles International plc, Blacks Leisure Group Plc, NCC AB, Animal Health International Inc, Software as a Service

First Reported Mar 18 2010 - Updated Mar 18 2010 - 2 Documents

AstraZeneca PLC

The drugs work: Biocompatibles sees further good sales growth ahead

In its preliminary full-year results statement, Biocompatibles International (LSE: BII) said it has continued to make very good progress in 2009 in terms of its financial performance and progress with its strategic goals. In the twelve months ended 31 ... [Published Mar 18 2010 by Proactive Investors.co.uk]

Entities: Biocompatibles International plc, Oncology, AstraZeneca PLC, Clinical Trials

First Reported Mar 18 2010 - Updated Mar 18 2010 - 1 Documents

Biocompatibles revenues up 50%

Medical technology firm Biocompatibles International's total revenues rose 50% to £26.6m in the year to the end of December - an increase of 29% on a constant currency basis.Gross profits rose 48% to £20.8m while operating loss increased 141% to £7.6 ... [Published Mar 18 2010 by MoneyAM]

Entities: Biocompatibles International plc, Medical Technology

First Reported Mar 18 2010 - Updated Mar 19 2010 - 1 Documents

Dunelm Group Plc

FTSE tipped to open slightly lower with BA still spotlighted

PRE-OPEN REPORT: Headline shares are tipped to open ten to fifteen points lower today, according to financial websites, backing away from the seventeen-month highs seen yesterday as profit-takers move in.British Airways will remain in the spotlight as ... [Published Mar 18 2010 by MoneyAM]

Entities: Powerflute Oyj, Sarantel, Dunelm Group Plc, Renewable Energy Generation Ltd, Aegis Group PLC

First Reported Mar 18 2010 - Updated Mar 18 2010 - 1 Documents

Salamander Energy PLC

What's in store today...

Thursday delivers a steaming batch of results in the shape of budget baker Greggs (GRG). The FTSE 250 group, which is targeting 50-60 new shop openings this year, is set to dish out a rise in full-year profits on the back of a robust Christmas ... [Published Mar 18 2010 by Interactive Investor Articles]

Entities: ProStrakan Group Plc, Greggs, Salamander Energy PLC

First Reported Feb 26 2010 - Updated Feb 26 2010 - 1 Documents

Eyecare Partners appoints CEO

Source: News BitesEyecare Partners Ltd appointed Michael Kotow as chief executive officer, effective March 2, 2010.Mr Kotow worked for Allergan Inc, Cooper Companies and Biocompatibles International, and also worked for Luxottica, Specsavers, ProVision ... [Published Feb 26 2010 by Business Spectator]

Entities: Turnover, CooperVision, The Cooper Companies Inc

First Reported Feb 17 2010 - Updated Feb 17 2010 - 5 Documents

First volunteer treated in Biocompatibles diabetes drug trial

Business Financial Newswire - The first volunteer has been treated in a clinical trial for CM3, a type II diabetes drug, Biocompatibles International said today (17 February).The phase I study is a single-centre, randomised, double-blind, placebo-controlled ... [Published Feb 17 2010 by Business Financial Newswire]

Entities: Biocompatibles International plc, Diabetes, non-insulin-dependent diabetes mellitus, Pharmacokinetics, clinical study

First Reported Feb 17 2010 - Updated Feb 18 2010 - 1 Documents

TechMARK movers: Biocompatibles starts trial

Medical technology developer Biocompatibles International has been boosted by the start of a phase I trial clinical trial for a potential diabetes drug.CM3 has been developed with AstraZeneca and it is aimed at type II diabetes. AstraZeneca paid 4.3m ... [Published Feb 17 2010 by Digital Look]

Entities: Biocompatibles International plc, AEA Technology, KCOM Group

First Reported Jan 08 2010 - Updated Jan 08 2010 - 1 Documents

Bullish Biocompatibles

Jan 2010 BII - Biocompatibles International Latest Prices Name Price % Biocompatibles International 232.50p 0.00% techMARK 1,595 +0.02% 3,524 +0.59% LONDON (SHARECAST) - Revenue was slightly ahead of expectations at medical technology company Biocompatibles ... [Published Jan 08 2010 by ShareCast]

Entities: Biocompatibles International plc, AstraZeneca PLC, Oncology

First Reported Jan 08 2010 - Updated Jan 08 2010 - 2 Documents

Biocompatibles says 2009 was ‘excellent’ and guides for 13 pct revenue rise in 2010

Medical technology group Biocompatibles International PLC (LSE: BII) said it had an “excellent year in 2009”, and that revenue and year-end cash levels came in ahead of its previous guidance. It is forecasting an around 13 percent rise in revenue for ... [Published Jan 08 2010 by Proactiveinvestors United Kingdom RSS feed]

Entities: Biocompatibles International plc, AstraZeneca PLC, Dividend, Clinical Trials

First Reported Dec 07 2009 - Updated Dec 07 2009 - 1 Documents

Biocompatibles and AstraZeneca to initiate clinical trials for anti-diabetes drug in January

Biocompatibles International (AIM: BII) and AstraZeneca (LSE: AZN) have announced that they will initiate clinical trials for their jointly developed type II anti-diabetes drug CM3 in January after the pre-clinical phase of the programme was completed ... [Published Dec 07 2009 by Proactiveinvestors United Kingdom RSS feed]

Entities: AstraZeneca PLC, Biocompatibles International plc, Clinical Trials

First Reported Nov 18 2009 - Updated Nov 18 2009 - 2 Documents

Biocompatibles adds to oncology portfolio

Nov 2009 BII - Biocompatibles International Latest Prices Name Price % Biocompatibles International 237.50p 0.00% techMARK 1,522 +0.60% 3,201 +0.06% LONDON (SHARECAST) - Drug device combination products developer Biocompatibles has snapped up the inventory ... [Published Nov 18 2009 by ShareCast]

Entities: Biocompatibles International plc, Oncology, melanoma, Diagnostic, Intellectual Property

Quotes

...latest prescription trends show Abstral (the rapidly relieving analgesic for breakthrough cancer pain) surprising us on the upside in Europe. "This year should be newsflow rich, with the potential for up to three US approvals. The route looks likely to involve a gradual evolution in product contributions, but ProStakan appears to be on track towards its EBITDA transformation." Finally, Salamander Energy (SMDR) will give investors food for thought with its own full year results...

What's in store today... [Interactive Investor Articles - Mar 18 2010]

The milestone payment was "triggered by the first dosing in a Phase II proof of concept clinical trial of AUY-922, an Hsp90 inhibitor, in a range of solid tumours" . Last month, Vernalis raised £28.5m net via a placing and open offer at 76p a share

TechMARK movers: Vernalis milestone [ShareCast - Mar 15 2010]

...The company said it had been granted the first of the relevant patents recently. "I am delighted that the CM-3 programme has passed this important milestone and I congratulate the team at our CellMed subsidiary on their significant achievement, Biocompatibles Chief Executive Crispin Simon commented. I look forward to announcing its progress into Phase II later in the year'.The investigational drug harnesses the GLP-1 peptide, which is naturally released into the stomach shortly after food intake to maintain normal blood-sugar levels and to control appetite. However the naturally occurring peptide is active for a very short duration due to its rapid degradation. Biocompatibles recent preclinical programme indicated that CM3 has an extended duration, as well as excellent tolerability compared to other GLP-1 mimetics."

Biocompatibles and AstraZeneca co-developed diabetes drug enters Phase I trial [Proactive Investors.co.uk - Feb 17 2010]

Biocompatibles and AstraZeneca co-developed diabetes drug enters Phase I trial [Proactiveinvestors United Kingdom RSS feed - Feb 17 2010]

More Content

sort by: Date \| Relevance
Small caps outperform blue chips as AIM All-Sha... [Proactive Investors.co.uk - 15 hours ago]
Small cap weekly news wrap: ECO Animal Health, ... [Proactive Investors.co.uk - 15 hours ago]
Small cap news wrap: ReNeuron Group, Biocompati... [Proactive Investors.co.uk - 15 hours ago]
Small caps outperform blue chips as AIM All-Sha... [Proactiveinvestors United Kingdom RSS feed - 23 hours ago]
Small cap weekly news wrap: ECO Animal Health, ... [Proactiveinvestors United Kingdom RSS feed - 23 hours ago]
Small cap news wrap: ReNeuron Group, Biocompati... [Proactiveinvestors United Kingdom RSS feed - 23 hours ago]
FTSE 100 flat as Dow Jones and NASDAQ gain, min... [Proactive Investors.co.uk - Mar 18 2010]
GlaxoSmithKline, Aggreko, Experian, TUI Travel ... [Proactive Investors.co.uk - Mar 18 2010]
FTSE 100 pares losses on positive US data, comm... [Proactive Investors.co.uk - Mar 18 2010]
TechMARK movers: ProStrakan cuts loss [Find - Mar 18 2010]
FTSE 100 flat as Dow Jones and NASDAQ gain, min... [Proactiveinvestors United Kingdom RSS feed - Mar 18 2010]
GlaxoSmithKline, Aggreko, Experian, TUI Travel ... [Proactiveinvestors United Kingdom RSS feed - Mar 18 2010]
FTSE 100 pares losses on positive US data, comm... [Proactiveinvestors United Kingdom RSS feed - Mar 18 2010]
The drugs work: Biocompatibles sees further goo... [Proactive Investors.co.uk - Mar 18 2010]
Biocompatibles revenues up 50% [MoneyAM - Mar 18 2010]
The drugs work: Biocompatibles sees further goo... [Proactiveinvestors United Kingdom RSS feed - Mar 18 2010]
FTSE tipped to open slightly lower with BA stil... [MoneyAM - Mar 18 2010]
What's in store today... [Interactive Investor Articles - Mar 18 2010]
TechMARK movers: Aveva boosted by broker upgrade [Find - Mar 16 2010]
TechMARK movers: Vernalis milestone [ShareCast - Mar 15 2010]
FTSE 100, Dow Jones, S&P 500 and NASDAQ see... [Proactive Investors.co.uk - Mar 14 2010]
FTSE 100 seen higher ahead of EU, US and UK inf... [Proactive Investors.co.uk - Mar 14 2010]
FTSE weekly preview: G4S, Wellstream Holdings, ... [Proactive Investors.co.uk - Mar 14 2010]
FTSE 100 seen flat on Monday amid lack of corpo... [Proactive Investors.co.uk - Mar 14 2010]
FTSE 100, Dow Jones, S&P 500 and NASDAQ see... [Proactiveinvestors United Kingdom RSS feed - Mar 14 2010]
FTSE 100 seen higher ahead of EU, US and UK inf... [Proactiveinvestors United Kingdom RSS feed - Mar 14 2010]
FTSE weekly preview: G4S, Wellstream Holdings, ... [Proactiveinvestors United Kingdom RSS feed - Mar 14 2010]
FTSE 100 seen flat on Monday amid lack of corpo... [Proactiveinvestors United Kingdom RSS feed - Mar 14 2010]
Week Ahead: G4S, Bank of England minutes [ShareCast - Mar 12 2010]
The week ahead... [Interactive Investor Articles - Mar 12 2010]